Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
March 03, 2022 08:01 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief...
F-star Therapeutics Appoints James Sandy as Chief Development Officer
March 01, 2022 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
FStar.jpg
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
January 05, 2022 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
FStar.jpg
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
December 07, 2021 09:05 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
FStar.jpg
F-star Therapeutics to Host Virtual R&D Day on December 6, 2021
November 29, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
LOGO.jpg
Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
November 08, 2021 08:30 ET | Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
lynx.png
Lynx Biosciences Closes Series Seed Equity Round Led by Checkmate Capital Group
November 03, 2021 10:00 ET | Lynx Biosciences, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lynx Biosciences, Inc. ("LynxBio®"), a San Diego-based biotechnology company, today announced the successful closing of its Series Seed Preferred Stock...
image.jpg
NANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICE
October 06, 2021 11:10 ET | Medlab Clinical Ltd
SYDNEY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX.MDC) is pleased to announce NanoCelle® the company’s proprietary delivery platform has been issued a “Notice of Allowance” by the...
FStar.jpg
F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
August 10, 2021 08:00 ET | F-star Therapeutics, Inc.
Patent protection in U.S. runs through 2037 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a...
FStar.jpg
F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
March 29, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...